Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1292

1.

Descending necrotizing mediastinitis caused by Streptococcus constellatus in an immunocompetent patient: case report and review of the literature.

Ye RH, Yang JC, Hong HH, Mao YP, Zhu YH, Cao Y, Wang Z.

BMC Pulm Med. 2020 Feb 17;20(1):43. doi: 10.1186/s12890-020-1068-3.

2.

HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.

Suskiewicz MJ, Zobel F, Ogden TEH, Fontana P, Ariza A, Yang JC, Zhu K, Bracken L, Hawthorne WJ, Ahel D, Neuhaus D, Ahel I.

Nature. 2020 Feb 6. doi: 10.1038/s41586-020-2013-6. [Epub ahead of print]

PMID:
32028527
3.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G.

Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30785-5. doi: 10.1016/S1470-2045(19)30785-5. [Epub ahead of print]

PMID:
32027846
4.

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.

Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI.

Lung Cancer (Auckl). 2019 Nov 13;10:125-130. doi: 10.2147/LCTT.S209231. eCollection 2019.

5.

Precision Management of Advanced Non-Small Cell Lung Cancer.

Yang CY, Yang JC, Yang PC.

Annu Rev Med. 2020 Jan 27;71:117-136. doi: 10.1146/annurev-med-051718-013524.

PMID:
31986082
6.

Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.

Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, Alvarez Secord A, Yang JC, Johnson FR, Gonzalez JM, Reed SD.

Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070-6. doi: 10.1016/j.ygyno.2020.01.026. [Epub ahead of print]

PMID:
31982178
7.

In situ environmental TEM observation of two-stage shrinking of Cu2O islands on Cu(100) during methanol reduction.

Chi H, Curnan MT, Li M, Andolina CM, Saidi WA, Veser G, Yang JC.

Phys Chem Chem Phys. 2020 Feb 7;22(5):2738-2742. doi: 10.1039/c9cp05831a. Epub 2020 Jan 21.

PMID:
31960012
8.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn YC, Kim TY, Ahn HK, Peters S, Yoshino T, Douillard JY.

Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.

PMID:
31959336
9.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW.

Lancet Respir Med. 2020 Jan 15. pii: S2213-2600(19)30267-X. doi: 10.1016/S2213-2600(19)30267-X. [Epub ahead of print]

PMID:
31954624
10.

The Antibacterial Efficacy and In Vivo Toxicity of Sodium Hypochlorite and Electrolyzed Oxidizing (EO) Water-Based Endodontic Irrigating Solutions.

Hsieh SC, Teng NC, Chu CC, Chu YT, Chen CH, Chang LY, Hsu CY, Huang CS, Hsiao GY, Yang JC.

Materials (Basel). 2020 Jan 7;13(2). pii: E260. doi: 10.3390/ma13020260.

11.

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.

Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES.

J Thorac Oncol. 2020 Jan 10. pii: S1556-0864(20)30014-9. doi: 10.1016/j.jtho.2019.12.126. [Epub ahead of print]

12.

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B.

Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P.

Hepatol Commun. 2019 Oct 10;4(1):8-20. doi: 10.1002/hep4.1436. eCollection 2020 Jan.

13.

Clinical and radiographic evaluation of different materials in primary molar pulpotomies: A retrospective study.

Lin CY, Kuo CL, Hsieh CY, Yang JC, Chang KT, Huang HT, Hsieh SC, Teng NC.

J Dent Sci. 2019 Dec;14(4):408-412. doi: 10.1016/j.jds.2019.08.001. Epub 2019 Sep 12. No abstract available.

14.

Parallel Signal Processing of a Wireless Pressure-Sensing Platform Combined with Machine-Learning-Based Cognition, Inspired by the Human Somatosensory System.

Lee GH, Park JK, Byun J, Yang JC, Kwon SY, Kim C, Jang C, Sim JY, Yook JG, Park S.

Adv Mater. 2019 Dec 16:e1906269. doi: 10.1002/adma.201906269. [Epub ahead of print]

PMID:
31840337
15.

Deauville Dubiosity.

Yang JC, Yahalom J.

Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):16. doi: 10.1016/j.ijrobp.2018.09.032. No abstract available.

PMID:
31836078
16.

Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17.

Yang JC, Roman-Urrestarazu A, Brayne C.

PLoS One. 2019 Dec 12;14(12):e0226349. doi: 10.1371/journal.pone.0226349. eCollection 2019.

17.

LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity.

Chang WC, Wang HC, Cheng WC, Yang JC, Chung WM, Ho YP, Chen L, Hung YC, Ma WL.

Endocr Relat Cancer. 2020 Feb;27(2):81-95. doi: 10.1530/ERC-19-0095.

PMID:
31815680
18.

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.

J Clin Oncol. 2020 Feb 20;38(6):538-547. doi: 10.1200/JCO.19.00457. Epub 2019 Dec 6.

PMID:
31809241
19.

Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.

Liao BC, Griesing S, Yang JC.

Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890286. doi: 10.1177/1758835919890286. eCollection 2019. Review.

20.

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.

Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ.

Eur J Cancer. 2020 Jan;124:110-122. doi: 10.1016/j.ejca.2019.10.019. Epub 2019 Nov 21.

PMID:
31760310
21.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Chan Ahn Y, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.

J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640-8. doi: 10.1016/j.jtho.2019.10.022. [Epub ahead of print] Review.

PMID:
31733357
22.

Intramuscular Hematoma on the Psoas Muscle.

Seo JG, Yang JC, Kim TW, Park KH.

Korean J Neurotrauma. 2019 Oct 15;15(2):234-238. doi: 10.13004/kjnt.2019.15.e29. eCollection 2019 Oct.

23.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT.

Lung Cancer. 2020 Jan;139:22-27. doi: 10.1016/j.lungcan.2019.10.015. Epub 2019 Oct 14.

PMID:
31706099
24.

Supermicrosurgical Lymphaticovenous Anastomosis as an Alternative Treatment Option for Patients with Lymphorrhea.

Yang JC, Yen YH, Wu SC, Lin WC, Chiang MH, Hsieh CH.

Plast Reconstr Surg. 2019 Nov;144(5):1214-1224. doi: 10.1097/PRS.0000000000006169.

PMID:
31688769
25.

Wasted Ganoderma tsugae Derived Chitosans for Smear Layer Removal in Endodontic Treatment.

Huang ST, Teng NC, Wang HH, Hsieh SC, Yang JC.

Polymers (Basel). 2019 Nov 1;11(11). pii: E1795. doi: 10.3390/polym11111795.

26.

Supermicrosurgical Lymphaticovenous Anastomosis as Alternative Treatment Option for Moderate-to-Severe Lower Limb Lymphedema.

Yang JC, Wu SC, Lin WC, Chiang MH, Chiang PL, Hsieh CH.

J Am Coll Surg. 2019 Oct 23. pii: S1072-7515(19)32143-X. doi: 10.1016/j.jamcollsurg.2019.10.007. [Epub ahead of print]

PMID:
31655173
27.

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.

Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC.

EMBO Mol Med. 2019 Dec;11(12):e10581. doi: 10.15252/emmm.201910581. Epub 2019 Oct 21.

28.

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, Wunderllich JR, Yang JC, Rosenberg SA.

J Clin Invest. 2019 Nov 1;129(11):4992-5004. doi: 10.1172/JCI127967.

29.

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.

Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M.

J Thorac Oncol. 2020 Jan;15(1):91-100. doi: 10.1016/j.jtho.2019.09.008. Epub 2019 Oct 9.

30.

A tri-ionic anchor mechanism drives Ube2N-specific recruitment and K63-chain ubiquitination in TRIM ligases.

Kiss L, Zeng J, Dickson CF, Mallery DL, Yang JC, McLaughlin SH, Boland A, Neuhaus D, James LC.

Nat Commun. 2019 Oct 3;10(1):4502. doi: 10.1038/s41467-019-12388-y.

31.

Cationic Polyelectrolyte for Anionic Cyanines: An Efficient Way To Translate Molecular Properties into Material Properties.

Li Z, Syed AA, Zhao P, Yang JC, Sharma R, Ensley TR, Matichak JD, Davydenko I, Jang SH, Hagan DJ, Marder SR, Van Stryland EW, Jen AK.

J Am Chem Soc. 2019 Oct 30;141(43):17331-17336. doi: 10.1021/jacs.9b08877. Epub 2019 Oct 15.

PMID:
31573193
32.

Reconstruction of pediatric hand injuries caused by automatic cup-sealing machines in Taiwan.

Tsai YJ, Carvajal CF, Flores NM, Lin TS, Yang JC, Chiang YC, Lin PY.

J Int Med Res. 2019 Nov;47(11):5855-5866. doi: 10.1177/0300060519874540. Epub 2019 Sep 26. No abstract available.

33.

Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.

Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Yang JC.

J Thorac Oncol. 2020 Jan;15(1):50-61. doi: 10.1016/j.jtho.2019.09.006. Epub 2019 Sep 23.

PMID:
31557536
34.

Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer.

Yang JC, Chang N, Wu DC, Cheng WC, Chung WM, Chang WC, Lei FJ, Liu CJ, Wu IC, Lai HC, Ma WL.

J Cell Mol Med. 2019 Nov;23(11):7417-7426. doi: 10.1111/jcmm.14605. Epub 2019 Sep 26.

35.

The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis.

Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK.

Acta Oncol. 2020 Jan;59(1):96-100. doi: 10.1080/0284186X.2019.1670354. Epub 2019 Sep 25. No abstract available.

PMID:
31552770
36.

Electronic Skin: Recent Progress and Future Prospects for Skin-Attachable Devices for Health Monitoring, Robotics, and Prosthetics.

Yang JC, Mun J, Kwon SY, Park S, Bao Z, Park S.

Adv Mater. 2019 Nov;31(48):e1904765. doi: 10.1002/adma.201904765. Epub 2019 Sep 19. Review.

PMID:
31538370
37.

Mutated RAS: Targeting the "Untargetable" with T Cells.

Chatani PD, Yang JC.

Clin Cancer Res. 2020 Feb 1;26(3):537-544. doi: 10.1158/1078-0432.CCR-19-2138. Epub 2019 Sep 11. Review.

PMID:
31511296
38.

Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms.

Johnson FR, DiSantostefano RL, Yang JC, Reed SD, Streffer J, Levitan B.

Value Health. 2019 Sep;22(9):1063-1069. doi: 10.1016/j.jval.2019.03.022. Epub 2019 Jul 20.

PMID:
31511183
39.

[Current problems and challenges for percutaneous endoscopic transforaminal lumbar interbody fusion].

Yang JC.

Zhonghua Yi Xue Za Zhi. 2019 Sep 3;99(33):2566-2568. doi: 10.3760/cma.j.issn.0376-2491.2019.33.002. Review. Chinese.

PMID:
31510713
40.

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.

Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA, Huang J.

Nat Commun. 2019 Sep 5;10(1):4016. doi: 10.1038/s41467-019-11869-4.

41.

Opioid prescription patterns in Germany and the global opioid epidemic: Systematic review of available evidence.

Rosner B, Neicun J, Yang JC, Roman-Urrestarazu A.

PLoS One. 2019 Aug 28;14(8):e0221153. doi: 10.1371/journal.pone.0221153. eCollection 2019.

42.

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.

Havrilesky LJ, Yang JC, Lee PS, Secord AA, Ehrisman JA, Davidson B, Berchuck A, Darcy KM, Maxwell GL, Reed SD.

Cancer. 2019 Dec 15;125(24):4399-4406. doi: 10.1002/cncr.32447. Epub 2019 Aug 27.

PMID:
31454432
43.

Iron-Catalyzed Decarboxylative Olefination of Unstrained Carbon-Carbon Bonds Relying on Alkoxyl Radical Induced Cascade.

Gao P, Wu H, Yang JC, Guo LN.

Org Lett. 2019 Aug 26. doi: 10.1021/acs.orglett.9b02675. [Epub ahead of print]

PMID:
31448922
44.

Temporal Ordering in Endocytic Clathrin-Coated Vesicle Formation via AP2 Phosphorylation.

Wrobel AG, Kadlecova Z, Kamenicky J, Yang JC, Herrmann T, Kelly BT, McCoy AJ, Evans PR, Martin S, Müller S, Sroubek F, Neuhaus D, Höning S, Owen DJ.

Dev Cell. 2019 Aug 19;50(4):494-508.e11. doi: 10.1016/j.devcel.2019.07.017.

45.

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.

Hong ST, Lin H, Wang CS, Chang CH, Lin AM, Yang JC, Lo YL.

J Nanobiotechnology. 2019 Aug 19;17(1):89. doi: 10.1186/s12951-019-0519-6.

46.

[Spatial pattern and evolutionary trend of sustainable development index of crop-livestock system: A case study in Shandong Province, China.]

Li Y, Sun ZG, Zhang XB, Yang JC, Hang S, Li SJ, Zhu WX, Lyu Y, Ouyang Z.

Ying Yong Sheng Tai Xue Bao. 2019 Jul;30(7):2371-2383. doi: 10.13287/j.1001-9332.201907.020. Chinese.

PMID:
31418241
47.

T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.

Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS.

J Clin Oncol. 2019 Oct 20;37(30):2759-2768. doi: 10.1200/JCO.18.02424. Epub 2019 Aug 13.

48.

Replicated Pattern Formation and Recognition Properties of 2,4-Dichlorophenoxyacetic Acid-Imprinted Polymers Using Colloidal Silica Array Molds.

Aya GA, Yang JC, Hong SW, Park JY.

Polymers (Basel). 2019 Aug 11;11(8). pii: E1332. doi: 10.3390/polym11081332.

49.
50.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T.

Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2.

Supplemental Content

Support Center